CION Ameerpet
Treatment Explained · Reviewed by CION Oncologists · NABH Accredited
Immunotherapy for Endometrial Cancer — And Who It Actually Helps
Immunotherapy is the genuine advance in endometrial cancer of the last decade, and it is also the treatment most often described in terms too vague to be useful. Here is the specific version. It works by releasing a brake on your own immune system so that it can see and attack the tumour. How well it works depends overwhelmingly on one property of your tumour — whether its DNA repair machinery is faulty. Where it is, responses have been substantial and durable in women whose options were previously limited. Where it is not, the picture is more modest, though combinations have improved it. Which is why every endometrial tumour is now tested.
- It works through your immune system — not by poisoning the tumour directly, as chemotherapy does
- MMR status is the deciding factor — mismatch repair deficient tumours respond far better
- Mainly for advanced or recurrent disease — not part of routine early-stage treatment
- One test decides eligibility — which is why every endometrial tumour is tested for it
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
How It Works, in Plain Terms
Your immune system is constantly checking cells and destroying ones that look wrong. It also has brakes — checkpoints — that stop it attacking healthy tissue. Without them, autoimmune disease would be the norm.
Tumours exploit those brakes. A cancer cell can display signals that press the checkpoint, effectively telling an approaching immune cell to stand down. Checkpoint inhibitors block that signal. The brake is released and the immune system, which was already there, is able to act.
Two consequences follow from that mechanism, and they explain almost everything else about this treatment:
- The tumour has to be visible to the immune system in the first place. Releasing a brake achieves nothing if there is nothing to see. Tumours carrying large numbers of mutations produce abnormal proteins that look foreign — and mismatch repair deficient tumours carry very many. This is the whole reason MMR status predicts response.
- Side effects are immune, not chemical. A less restrained immune system can attack healthy tissue too. That produces a quite different side-effect profile from chemotherapy — inflammation of the thyroid, bowel, skin, liver or lungs rather than hair loss and low blood counts.
- Responses can outlast the treatment. Where it works, the immune system has been taught something, and responses in this setting have often proved durable. That is genuinely different from most drug treatment in advanced cancer.
In line with our policy on these pages, treatment is described by class rather than by naming individual medicines — which drug, at what dose, is a decision for the oncologist treating you. The treatment page carries the specifics: see endometrial cancer treatment.
Did You Know? Endometrial cancer turns out to be one of the most mismatch-repair-deficient cancers there is — roughly a quarter to a third of endometrial tumours show loss of mismatch repair function, a far higher proportion than most solid cancers. That is why immunotherapy has had a larger effect here than in many other diseases. Most of those deficiencies are acquired within the tumour itself and are not inherited, but a minority signal Lynch syndrome, an inherited condition with implications for the whole family. A single test therefore does three jobs at once: it predicts response to immunotherapy, it contributes to the molecular classification now built into FIGO staging, and it flags who should be offered genetic counselling. Sources: NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; The Cancer Genome Atlas integrated genomic characterisation of endometrial carcinoma; FIGO 2023 staging for cancer of the endometrium.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Who It Helps, and How Much
The honest answer differs a great deal between groups, and being told “immunotherapy is available for endometrial cancer” without this detail is not much use.
| MMR deficient (dMMR / MSI-H) | MMR proficient (pMMR) | |
|---|---|---|
| How common | Roughly a quarter to a third of endometrial cancers — a high proportion by the standards of solid tumours. | The majority. Includes most low-grade endometrioid tumours and most serous cancers. |
| Response to checkpoint blockade alone | Substantial, and in a meaningful proportion of women durable — the strongest single reason this class matters in this disease. | Much more limited as a single agent, which is why it is not generally used alone in this group. |
| Usual role | An established option in advanced or recurrent disease, and increasingly considered alongside chemotherapy rather than only after it. | Used in combination with targeted treatment, which has extended its usefulness considerably in this group. |
| What else the result means | A minority signal Lynch syndrome and should prompt genetic counselling — with implications for the whole family. | No Lynch implication from this result. Other molecular findings, such as p53 status, may still shape treatment. |
| Where the result comes from | Immunohistochemistry on tumour tissue, sometimes with molecular MSI testing. See MMR and MSI testing. | The same test, reported as proficient or retained. |
If you have advanced or recurrent endometrial cancer and do not know your MMR status, that is the first thing to establish. It can almost always be tested on tissue already stored from an earlier biopsy or operation — no new procedure is usually needed. It is a short conversation with a clear answer, and it can change what is available to you.
Not Sure Whether Your Tumour Has Been Tested?
It is usually possible to test tissue already stored from an earlier biopsy or operation. Bring your reports and we will check.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
One Test Can Change What Is Available to You
MMR and MSI testing is done on every endometrial tumour here. If yours has not been tested, it usually still can be.
The practical detail
What Having Immunotherapy Is Actually Like
It is a very different experience from chemotherapy, and women who have had both are often surprised by how much less it disrupts ordinary life — and by which things they have to watch for instead.
How it is given
By a drip into a vein, in a day-care unit, at intervals of a few weeks. The infusion itself is relatively short and you go home the same day. There is no need for the scalp cooling, mouth care and anti-sickness regimens that surround chemotherapy, because the mechanism is entirely different. Most women continue working and living normally between cycles. Treatment continues as long as it is working and is being tolerated, which in this setting can be a considerable time, with periodic scans to assess response.
What the side effects feel like
Fatigue is the commonest, and it is usually milder than with chemotherapy. Rash and itching are frequent and generally manageable. The distinctive risks are immune-mediated: inflammation of the thyroid, bowel, liver, lungs, or less commonly other endocrine glands. Most are mild and treatable, but they are not like chemotherapy side effects and cannot be managed the same way — which is why you will have blood tests including thyroid function before each cycle, and why the team asks apparently unrelated questions about bowels, breathing and energy.
The one rule that matters: report things early
This is the single most important piece of practical advice about immunotherapy. Immune side effects are highly treatable when caught early and can become serious if left. New or worsening diarrhoea, a persistent cough or breathlessness, unusual tiredness, yellowing of the skin or eyes, or a rash that is spreading all need reporting the same day rather than at the next appointment. Patients are often reluctant to bother the team over what feels minor; here, that reluctance is the risk. You will be given a number to call, and it is there to be used.
Why steroids are involved
When an immune side effect occurs, the usual treatment is corticosteroids — damping down the immune activity that has turned on healthy tissue. This surprises people, since the point of the treatment was to activate the immune system. In practice the anti-tumour effect often persists even after steroids have settled an inflammatory side effect. It is also why you should tell any other doctor treating you, including in an emergency department, that you are on immunotherapy: the management of, say, colitis is quite different in someone receiving checkpoint blockade.
How response is judged, and the scan that looks worse
Response is assessed on scans at intervals, alongside how you feel. One phenomenon is worth knowing about in advance: occasionally an early scan appears to show a tumour that has grown, when what has actually happened is that immune cells have flooded into it. This is uncommon, but it is real, and it is one reason an oncologist may recommend continuing and rescanning rather than switching treatment on the strength of a single image. If that decision is proposed to you, it is not indecision — ask them to explain the reasoning.
Combination with targeted treatment
For women whose tumours are mismatch repair proficient, checkpoint blockade alone does relatively little. Combining it with targeted treatment that acts on tumour blood supply and signalling has substantially improved outcomes in this larger group, and is an established option in advanced or recurrent disease after chemotherapy. The combination is more demanding than immunotherapy alone — blood pressure, thyroid function and fatigue all need active management — and that trade-off should be discussed openly. See targeted therapy.
Told There Are No Further Options?
If molecular testing has not been done, that conclusion may be premature. It is worth one appointment to check. The opinion is free.
Where It Fits in the Overall Plan
Immunotherapy is not part of routine treatment for early endometrial cancer, and it is worth being clear about that, because women who have had a hysterectomy for a stage 1 tumour sometimes read about it and wonder whether they are missing out. They are not: for early-stage disease, surgery with or without radiation is the established treatment, and immunotherapy has no established routine role there.
Where it belongs at present:
- Advanced disease at diagnosis. For stage 4 disease, and increasingly considered alongside chemotherapy from the outset in mismatch repair deficient tumours rather than held back until later.
- Recurrent disease. Where endometrial cancer returns after earlier treatment, it is a central option and MMR status is one of the first things established. See treating recurrent disease.
- Under study for higher-risk early disease. Whether adding immunotherapy helps women with high-risk, node-positive or aggressive-histology disease treated with curative intent is an active research question rather than settled practice.
- Not a substitute for surgery. Where a tumour can be removed, removing it remains the treatment. See hysterectomy for endometrial cancer.
A note on cost. Immunotherapy is expensive, and that is a real factor for most families in India. It is worth asking directly about the total expected cost, about what your insurance or state scheme cover will meet, and about patient assistance programmes, before treatment begins rather than partway through. See also immunotherapy cost.
Why Testing Every Tumour Matters
A treatment you are eligible for is no use if nobody established that you were eligible.
MMR / MSI testing as standard
Lynch counselling built in
Tumour board for every diagnosis
One place for the whole pathway
Costs explained before you commit
Decisions for healing, not billing
Take The Next Step
The Answer Might Already Be in Stored Tissue
If your tumour has not been tested for mismatch repair status, that is usually fixable without another procedure.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy for Endometrial Cancer — Frequently Asked Questions
Who can have immunotherapy for endometrial cancer?
It is used mainly in advanced or recurrent disease rather than as part of routine early-stage treatment. Within that setting, the key question is your tumour's mismatch repair status. Tumours that are mismatch repair deficient — reported as dMMR, or as microsatellite instability high — respond markedly better, because the faulty DNA repair machinery leaves them carrying very large numbers of mutations that make them visible to the immune system. Roughly a quarter to a third of endometrial cancers fall into this group, which is high compared with most solid tumours. For women whose tumours are mismatch repair proficient, checkpoint blockade alone does relatively little, but combining it with targeted treatment has improved outcomes considerably.
How is immunotherapy different from chemotherapy?
They work in completely different ways and feel completely different. Chemotherapy attacks rapidly dividing cells directly, which is why it causes hair loss, mouth soreness, nausea and low blood counts. Immunotherapy does not attack the tumour at all — it releases a brake on your own immune system so that it can. That produces a different side-effect profile: fatigue and rash are common, and the distinctive risks are immune-mediated inflammation of the thyroid, bowel, liver, lungs or other organs. Most women find it considerably less disruptive to daily life. It is given as a drip every few weeks in a day unit, and many people continue working throughout.
What is MMR testing and why does it matter so much?
Mismatch repair is the cell's system for proofreading DNA and correcting copying errors. MMR testing establishes whether that system is working in your tumour, usually by immunohistochemistry looking for the four mismatch repair proteins, sometimes supported by molecular testing for microsatellite instability. It matters for three separate reasons. It predicts response to checkpoint inhibitor immunotherapy, which is the most direct treatment consequence. It contributes to the molecular classification now built into FIGO staging. And a minority of deficient results signal Lynch syndrome, an inherited condition that has implications for your children, siblings and parents, and that should prompt genetic counselling.
What side effects should I report urgently?
This is the most practically important thing to know about immunotherapy, because immune side effects are very treatable early and can become serious if left. Report the same day, rather than waiting for your next appointment: new or worsening diarrhoea, particularly if frequent or with blood; a persistent cough or new breathlessness; unusual or severe tiredness; yellowing of the skin or eyes; a rash that is spreading or blistering; and severe abdominal pain. Also tell any other doctor treating you, including in an emergency department, that you are on immunotherapy, because conditions such as colitis are managed differently in someone receiving checkpoint blockade. You will be given a number to call — it exists to be used.
Is immunotherapy a cure for endometrial cancer?
It is not a cure, and any source describing it that way should be treated with caution. What it has genuinely done is change outcomes for a defined group of women with advanced or recurrent disease whose previous options were limited. In mismatch repair deficient tumours, responses have been substantial and — unusually for advanced cancer treatment — often durable, meaning they persist for a considerable time. That is a real advance and worth pursuing. It is not the same as cure, it does not work for everyone even within the group most likely to benefit, and it has no established role in routine early-stage treatment, where surgery remains the treatment that removes the cancer.
Medical disclaimer: This page describes immunotherapy for endometrial cancer in general terms and is reviewed by a CION oncologist, following current NCCN and ESGO–ESTRO–ESP guidance. In line with our editorial policy it describes treatment by drug class rather than naming individual medicines; which drug, at what dose and in what combination is an individual clinical decision. It is not advice about your own treatment, and eligibility depends on testing performed on your tumour. If you are receiving immunotherapy and develop a new symptom, contact your oncology team the same day.